Graphene Trace is proud to announce the successful close of our £250,000 pre-seed investment round, led by SFC Capital. This funding marks a significant milestone in our journey to bring advanced, real-time pressure mapping technology to the forefront of clinical care and pressure ulcer prevention.
The investment will enable us to accelerate development of our Sensore platform by finalising the design of our next-generation prototype, scaling up small-batch manufacturing for early adopters, and initiating the regulatory and clinical trial processes required to bring our technology to market. These are critical next steps as we prepare to demonstrate both the clinical and commercial value of our solution across care and hospital settings.
We’re delighted to be partnering with SFC Capital, one of the UK’s most active early-stage investors, whose support reflects strong confidence in our team, technology, and vision for improving patient outcomes through data-driven care.
This funding allows us to build on the momentum we’ve already generated through early partnerships, feasibility work, and our ongoing engagement with clinicians and frontline care staff. We remain committed to co-developing solutions that are not only technically advanced, but truly aligned with the needs of patients and professionals alike.
We’re incredibly grateful to SFC Capital and our early supporters for helping make this next phase possible—and we’re looking forward to sharing more in the coming year
Scott Dean
CEO
Share
